Milestone Enrolls First Canadian Patient in ReVeRA-301
MONTREAL and CHARLOTTE, N.C. — September 24, 2026 Milestone Pharmaceuticals Inc. announced that the Montreal Heart Institute has enrolled...
atrial fibrillation
Advertisement
Field Medical Reports 12-Month Field PULSE Trial Results
Atlanta and Carlsbad, California, September 20, 2026 Field Medical, Inc. has announced publication of 12-month results from its first-in-human...
CardiaCare Raises Seed Funding for Cardiac Clinical Studies
Rehovot, Israel, September 18, 2026 CardiaCare, a medical device company developing wearable technology for cardiac arrhythmias, has announced the...
Bayer Advances GIRK4 Inhibitor Into Phase II for Atrial Fibrillation
BERLIN — September 9, 2026 Bayer announced the initiation of a global Phase II clinical trial of BAY 3670549,...
Novartis Showcases Next-Generation Cardiovascular Therapies
BASEL, Switzerland, August 19, 2026 Novartis will present data from 10 abstracts across its cardiovascular portfolio at the 2026...
Advertisements
Johnson & Johnson Wins FDA Approval for Dual Energy Platform
IRVINE, Calif., July 8, 2026 Johnson & Johnson MedTech has announced that the U.S. Food and Drug Administration (FDA)...
TCAI and St. David’s Medical Center Advance Cardiac Rhythm Innovation
Austin, Texas, USA — May 22, 2026 The Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center has...
Medtronic Affera Catheters Show Strong HRS 2026 Data
Galway, Ireland & Chicago, Illinois | April 25, 2026 Medtronic has announced significant clinical milestones for its Affera™ mapping...
Haemonetics VASCADE MVP XL Shows Superior Closure
BOSTON, April 24, 2026 Haemonetics Corporation has announced compelling new clinical data demonstrating the safety, efficacy, and superior performance...
Johnson & Johnson Launches VARIPULSE Pro in Europe
IRVINE, California, United States, April 7, 2026 Johnson & Johnson MedTech announced the European launch of VARIPULSE™ Pro, an...
Advertisement
